Considering that a16z said that they are focusing on software around biotech and not on traditional biotech I think it makes sense that they aren't talking about regulatory hurdles or the cost to bring a drug to market. Eroom's law is a serious problem, and it is hard to imagine a disruptive startup that could compete in that environment.